Analyst consensus rating
Crescent Biopharma Analyst Rating: Strong Buy
Direct answer
Crescent Biopharma's consensus rating is Strong Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $31.50.
Forecast evidence checked October 18, 2026.
Get free Crescent Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $11.84
- Average price target
- $31.50
- High price target
- $36.00
- Low price target
- $27.00
- Low target gap
- +128%
- Target upside
- +166%
- High target gap
- +204.1%
- Target range width
- 76%
- Consensus rating
- Strong Buy
- Analysts
- 6
- Evidence date
- October 18, 2026
- Valid through
- October 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Crescent Biopharma?
Crescent Biopharma has a verified Strong Buy consensus. The same dataset has an average price target of $31.50.
How far are Crescent Biopharma's low and high targets from the recorded price?
The low target implies +128%, while the high target implies +204.1%.
How many analysts are included in Crescent Biopharma's consensus?
The verified consensus includes 6 analysts.
How is Crescent Biopharma's target upside or downside calculated?
The average target of $31.50 is divided by the recorded price of $11.84, then one is subtracted to produce +166%. This does not guarantee a future return.
When was Crescent Biopharma's analyst forecast verified?
The data was verified on 2026-10-18. The dataset is valid through 2026-10-25.